Kayothera, Inc. Strengthens Financial Position With $5.2 Million In Grant And Expanded Series A Funding, Bringing Total Financial Support To $14 Million
Kayothera, Inc. Strengthens Financial Position With $5.2 Million In Grant And Expanded Series A Funding, Bringing Total Financial Support To $14 Million
07/19/23, 1:01 PM
Location
princetonIndustry
therapeutics
biotechnology
health care
Round Type
series a
Investors
Kayo Thera, Wrf Capital, Pier 70 Ventures, Bio Advance, Alsp, Andy Hill Cancer Research Endowment Fund3, National Institutes Of Health Small Business Innovation Research, New Jersey Health Foundation, Accelerator Life Science Partners
KayoThera, Inc. (“KayoThera”), an early-stage therapeutics company developing first-in-class, oral, small molecule inhibitors of the retinoid pathway, today announces the strengthening of its financial resources through multiple grant awards and expansion of its previously announced Series A financing. The expanded financing was led by Accelerator Life Science Partners (ALSP), who also provided Series A funding for KayoThera. With the additional $5.2 million in new equity investments, non-dilutive grant funding, and initial seed funding from the New Jersey Health Foundation, KayoThera’s total financial support to date is $14 million.
Company Info
Location
155 village blvd., suite 130
princeton, west virginia, united states
Additional Info
KayoThera, Inc. is an early-stage therapeutics company focused on the development of first-in-class, oral, small molecule inhibitors of the retinoid pathway. This pathway plays a critical role in a variety of serious diseases, including cardiometabolic diseases and cancer. KayoThera is developing therapies to treat diabetes and late-stage and metastatic cancers including breast, lung, pancreatic, colorectal, brain, and kidney cancers. The company was founded based on discoveries from Dr. Mark Esposito’s post-doctoral research at Princeton University and professor Yibin Kang, Ph.D. For more information, visit www.kayothera.com.